This free survey is powered by
  1. Surveys
  2. 2013
  3. February
  4. K
  5. KCI8 - v2
0%
Questions marked with an * are required Exit Survey
 
 
If you are receiving this survey before your interview…
Thank you for taking the time before our discussion to complete this survey. This survey will serve to both put our discussion in context and also help guide the conversation we have scheduled. Your responses and personal information are strictly confidential and we thank you in advance for your participation. At the end of this survey, we do request that you enter your mailing address so that we may send you your honorarium.

If you are receiving this survey after your interview…
Thank you for taking time earlier to talk to us about the wound care market. This survey is a short follow-up to that conversation to clarify some specifics that we may not have been able to discuss. Your responses and personal information are strictly confidential and we thank you in advance for your participation. At the end of this survey, we do request that you enter your mailing address so that we may send you your honorarium.
 
 
What is your name?
* First Name : 
* Last Name : 
 
 
 
* What is the primary setting in which you treat wound care patients? (Please select one)
 
Hospital
 
Wound care clinic
 
Private practice
 
Nursing home/skilled nursing facility
 
VA
 
Other (Please specify)
 
 
 
 
* What is your primary speciality? (Please select one)
 
Primary care
 
Plastic surgery
 
General surgery
 
Vascular surgery
 
Podiatry
 
Nurse/nurse practitioner
 
Other (Please specify)
 
 
 
 
We would like to ask you a few questions on the number of patients and wounds you treat for diabetic foot ulcers and venous leg ulcers. Please provide your best estimates.
 
 
 
* How many wound patients do you treat per week?
   
 
 
 
* How many diabetic foot ulcers (DFU) patients do you treat per week?
   
 
 
 
* How do you expect the number of DFU patients to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
 
* What percentage of DFU patients present with more than one chronic wound (enter a number 0-100)?
   
 
 
 
* How many venous leg ulcers (VLU) patients do you treat per week?
   
 
 
 
* How do you expect the number of VLU patients to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
 
* What percentage of VLU patients present with more than one chronic wound (enter a number 0-100)?
   
 
 
 
For the remainder of this survey, the following definitions for wound care therapy are as follows:
 
 
 
 
When selecting a treatment for chronic wound patient, please rate the following criteria in terms of importance in impacting your treatment selection on a scale of 1-7 (where 1=Not important and 7=Very important).
1 (Not Important) 2 3 4 5 6 7 (Very important) N/A
* Product effectiveness in promoting healing
* Being the safest available treatment option
* Can be used on a wide variety of wounds (e.g., type, size, depth)
* Relationship with sales representatives of product
* Time to initiating therapy (e.g., wait time for use of a product based on FDA label indication)
* Financial and economic impact to your facility (e.g., reimbursement rates of therapy)
* Patient preference / ability to manage treatment and follow-ups (e.g., patient ability to change dressings, burden on quality of life)
* Financial impact to patient (e.g., co-pays)
* Approval type (e.g. PMA, 510K)
* Administrative burden (e.g., prior authorizations, paperwork required)
* Endorsement or recommendation of a product / therapy from colleague or other physician
* Logistics and ease of use (e.g. temperature storage requirements, ordering lead times, easy prep process)
* Has a long shelf life
 
 
 
We will now focus a few of our questions on diabetic foot ulcers.
 
 
 
* Of the total number of DFU wounds you treated in a year, what percentage received advanced therapy (e.g., skin substitute, NPWT, HBO)? Please enter a number 0-100.
   
 
 
 
For the purposes of this survey, skin substitute therapy is considered medically appropriate for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than three weeks duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule, or bone exposure.
 
 
 
* Of the total number DFU wounds you treat in a year, what percentage are medically appropriate for skin substitution therapy (e.g., Apligraf, Dermagraft, Graftjacket, Oasis)? Please enter a number 0-100.
   
 
 
 
* How do you expect the number of medically appropriate DFU wounds to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
 
* Of the total number of medically appropriate DFU wounds treated in a year, what percentage is actually treated with skin substitution therapy? Please enter a number 0-100.
   
 
 
 
* How do you expect the number of medically appropriate DFU wounds actually treated with skin substitution therapy to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
 
* Of the patients who received skin substitution therapy, what percentage of patients required more than one skin substitution treatment to achieve complete wound closure (e.g., how many required more than one session/office visit for each wound)? Please enter a number 0-100.
   
 
 
 
* What is the average number of applications of skin substitutions per wound at each treatment? (e.g., how many units of product are used on each wound in one visit)
   
 
 
 
* Of the DFU wounds medically appropriate for skin substitution you treat in a year, what was your percentage usage of the following products? Please note that usage should total 100%.
Conventional therapies (e.g., alginates, bandages)
Apligraf
Dermagraft
Oasis
Graftjacket
Other advanced therapies (e.g., HBO, NPWT)
0
Values must add up to 100
 
 
 
* In the last 100 diabetic foot ulcers you saw where you would have preferred to use skin substitute therapy but could not, what was the primary reason you did not use skin substitute therapy? Please allocate 100 points across the following categories. If a category is not relevant / does not prevent you from using skin substitute therapy, please leave it blank.
Financial burden to patient (e.g., co-pay)
Moisture level
Preference for other types of treatment
Wound infection
Nurse skill level / unfamiliarity with product
Administrative burden / documentation requirements / logistics of getting a patient on therapy
Wound location
Wound depth
Other
Financial burden on site
Patient refuses therapy
Not covered by payer
Too much wound necrosis
Concerned about patient compliance
Incompatibility with standard of care
Time required to manage (i.e., frequency of dressing changes) or burdensome follow-up requirements (e.g., mismatch between follow-up visits required for skin substitute therapy and follow-up visits required for other aspects of patient care)
0
Values must add up to 100
 
 
 
We will now focus a few of our questions on venous leg ulcers.
 
 
 
* Of the total number of VLU wounds you treated in a year, what percentage received advanced therapy (e.g., skin substitute, NPWT, HBO)? Please enter a number 0-100.
   
 
 
 
Based on our research, we believe that skin substitute therapy is considered appropriate treatment for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1 month duration and which have not adequately responded to conventional ulcer therapy.
 
 
 
* Of the total number VLU wounds you treat in a year, what percentage are medically appropriate for skin substitution therapy (e.g., Apligraf, Graftjacket, Oasis)? Please enter a number 0-100.
   
 
 
 
* How do you expect the number of medically appropriate VLU wounds to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No chnage
 
 
 
* Of the total number of medically appropriate VLU wounds treated in a year, what percentage is actually treated with skin substitution therapy? Please enter a number 0-100.
   
 
 
 
* How do you expect the number of medically appropriate VLU wounds actually treated with skin substitution therapy to change over the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
 
* Of the patients who received skin substitution therapy, what percentage of patients required more than one skin substitution treatment to achieve complete wound closure (e.g., how many required more than one session/office visit for each wound)? Please enter a number 0-100.
   
 
 
 
* What is the average number of applications of skin substitutions per wound at each treatment? (e.g., how many units of product are used on each wound in one visit)
   
 
 
 
* Of the VLU wounds medically appropriate for skin substitution you treat in a year, what was your percentage usage of the following products? Please note that usage should total 100%.
Conventional therapies (e.g., alginates, bandages)
Apligraf
Oasis
Graftjacket
Other advanced therapies (e.g., HBO, NPWT)
0
Values must add up to 100
 
 
 
* In the last 100 venous leg ulcers you treated where you would have preferred to use skin substitute therapy but could not, what was the primary reason you did not use skin substitute therapy? Please allocate 100 points across the following categories. If a category is not relevant / does not prevent you from using skin substitute therapy, please leave it blank.
Nurse skill level / unfamiliarity with product
Wound depth
Financial burden to patient (e.g., co-pay)
Other
Incompatibility with standard of care
Financial burden on site
Wound location
Not covered by payer
Wound infection
Concerned about patient compliance
Preference for other types of treatment
Too much wound necrosis
Administrative burden / documentation requirements / logistics of getting a patient on therapy
Moisture level
Patient refuses therapy
Time required to manage (i.e., frequency of dressing changes) or burdensome follow-up requirements (e.g., mismatch between follow-up visits required for skin substitute therapy and follow-up visits required for other aspects of patient care)
0
Values must add up to 100
 
 
 
We will now focus a few of our questions on specific products within the skin substitution space.
 
 
 
* Which of the following products do you use or have used in the past? Please select all that apply.
 
Apligraf
 
Dermagraft
 
Oasis
 
None of the above

 
 
 
* If you currently use Apligraf, how many units does your center order per week?
 
More than 5 shipments / week
 
3-5 shipments / week
 
1-3 shipments / week
 
I do not use Apligraf / I do not know
 
 
 
* How has your usage of Apligraf changed in the last 2 years? Please give a percentage change.
 
Increased
 
Decreased
 
No change
 
 
 
* How do you expect your usage of Apligraf to change in the next 3 years? Please give a percentage change.
 
Increase
 
Decrease
 
No change
 
 
Please rate how strongly you agree with the following statements about your usage of Apligraf relative to other skin substitution products (e.g., Dermagraft, Oasis) (where 1=Strongly disagree and 7=Strongly agree).
1 (Strongly disagree) 2 3 4 5 6 7 (Strongly agree) N/A
* I have a better relationship with Dermagraft, Oasis, etc. suppliers than with Apligraf suppliers
* I prefer the storage and handling of other therapies over Apligraf
* I believe that other skin substitution treatments are more efficacious than Apligraf
* I have very little knowledge about Apligraf compared to its competitors
* I tried Dermagraft, Oasis, etc. first and have found no reason compelling reason to try Apligraf
 
 
 
* In the last 100 diabetic foot ulcers and venous leg uclers you saw where you would have preferred to use Apligraf but could not, what was the primary reason you did not use Apligraf? Please allocate 100 points across the following categories. If a category is not relevant / does not prevent you from using Apligraf, please leave it blank.
Financial burden on site
Other
Time required to manage (i.e., frequency of dressing changes) or burdensome follow-up requirements (e.g., mismatch between follow-up visits required for skin substitute therapy and follow-up visits required for other aspects of patient care)
Not covered by payer
Too much wound necrosis
Wound location
Financial burden to patient (e.g., co-pay)
Patient refuses therapy
Wound depth
Incompatibility with standard of care
Concerned about patient compliance
Administrative burden / documentation requirements / logistics of getting a patient on therapy
Nurse skill level / unfamiliarity with product
Preference for other types of treatment
Moisture level
Wound infection
0
Values must add up to 100
 
 
Please rate Apligraf performance on the following criteria, where 1=Poor performance and 7=Very strong performance.
1 (Poor performance) 2 3 4 5 6 7 (Very strong performance) N/A
* Relationship with sales representatives of product
* Time to initiating therapy (e.g., wait time for use of a product based on FDA label indication)
* Product effectiveness in promoting healing
* Logistics and ease of use (e.g. temperature storage requirements, ordering lead times, easy prep process)
* Being the safest available treatment option
* Financial and economic impact to your facility (e.g., reimbursement rates of therapy)
* Approval type (e.g. PMA, 510K)
* Financial impact to patient (e.g., co-pays)
* Can be used on a wide variety of wounds (e.g., type, size, depth)
* Patient preference / ability to manage treatment and follow-ups (e.g., patient ability to change dressings, burden on quality of life)
* Has a long shelf life
* Administrative burden (e.g., prior authorizations, paperwork required)
* Is endorsed or recommended by my colleagues / other physicians
 
 
Please rate Dermagraft performance on the following criteria, where 1=Poor performance and 7=Very strong performance.
1 (Poor performance) 2 3 4 5 6 7 (Very strong performance) N/A
* Has a long shelf life
* Financial impact to patient (e.g., co-pays)
* Financial and economic impact to your facility (e.g., reimbursement rates of therapy)
* Patient preference / ability to manage treatment and follow-ups (e.g., patient ability to change dressings, burden on quality of life)
* Product effectiveness in promoting healing
* Being the safest available treatment option
* Is endorsed or recommended by my colleagues / other physicians
* Approval type (e.g. PMA, 510K)
* Can be used on a wide variety of wounds (e.g., type, size, depth)
* Administrative burden (e.g., prior authorizations, paperwork required)
* Logistics and ease of use (e.g. temperature storage requirements, ordering lead times, easy prep process)
* Relationship with sales representatives of product
* Time to initiating therapy (e.g., wait time for use of a product based on FDA label indication)
 
 
Please rate Oasis performance on the following criteria, where 1=Poor performance and 7=Very strong performance.
1 (Poor performance) 2 3 4 5 6 7 (Very strong performance) N/A
* Patient preference / ability to manage treatment and follow-ups (e.g., patient ability to change dressings, burden on quality of life)
* Approval type (e.g. PMA, 510K)
* Relationship with sales representatives of product
* Financial and economic impact to your facility (e.g., reimbursement rates of therapy)
* Administrative burden (e.g., prior authorizations, paperwork required)
* Has a long shelf life
* Can be used on a wide variety of wounds (e.g., type, size, depth)
* Being the safest available treatment option
* Product effectiveness in promoting healing
* Time to initiating therapy (e.g., wait time for use of a product based on FDA label indication)
* Is endorsed or recommended by my colleagues / other physicians
* Logistics and ease of use (e.g. temperature storage requirements, ordering lead times, easy prep process)
* Financial impact to patient (e.g., co-pays)
 
 
 
We would like to now ask a few questions on the diagnosis rate and usage of skin substitute therapy for both DFU and VLU.
 
 
 
* Overall, what is the diagnosis rate for DFU patients? For example, for every 100 patients having DFUs, how many are diagnosed with a DFU? Please enter a number between 0-100.
   
 
 
 
* How do you expect the number of diagnosed DFU patients to change in the next 3 years?
 
Increase
 
Decrease
 
No change
 
 
 
* Overall, what is the treatment rate for DFU patients? For example, for every 100 patients with DFUs, how many are actually treated for a DFU (e.g., receive conventional or advanced therapy). Conventional may include alginates, dressings, etc. and advanced may include skin substitutes or other advanced therapies. Please enter a number between 0-100.
   
 
 
 
* Of the DFU patients who receive skin substitute , what is the average number of treatments required for complete wound closure (e.g., visits to the office for treatment)? Please enter a number.
   
 
 
 
* Overall, what is the diagnosis rate for VLU patients? For example, for every 100 patients having VLUs, how many are diagnosed with a VLU? Please enter a number between 0-100.
   
 
 
 
* How do you expect the number of diagnosed VLU patients to change in the next 3 years?
 
Increase
 
Decrease
 
No change
 
 
 
* Overall, what is the treatment rate for VLU patients? For example, for every 100 patients with VLUs, how many are actually treated for a VLU (e.g., receive conventional or advanced therapy). Conventional may include alginates, dressings, etc. and advanced may include skin substitutes or other advanced therapies. Please enter a number between 0-100.
   
 
 
 
* Of the VLU patients who receive skin substitute , what is the average number of treatments required for complete wound closure (e.g., visits to the office for treatment)? Please enter a number.
   
 
 
 
* Please provide us with your mailing address so that we may send you your honorarium.